Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tiratricol - Egetis Therapeutics

Next Previous
Search
Drug Profile

Tiratricol - Egetis Therapeutics

Alternative Names: Emcitate; RTT-01; TA-3; Teatrois; Triac; Triiodothyroacetic-acid

Latest Information Update: 07 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rare Thyroid Therapeutics
  • Developer Egetis Therapeutics; Rare Thyroid Therapeutics
  • Class Acetic acids; Iodobenzenes; Phenols; Phenyl ethers; Small molecules
  • Mechanism of Action Thyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid hormone resistance syndrome; Allan-Herndon-Dudley syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Allan-Herndon-Dudley syndrome

Most Recent Events

  • 13 Feb 2025 Egetis Therapeutics plans to launch tiratricol for Allan Herndon Dudley syndrome in Europe in second quarter of 2025
  • 13 Feb 2025 Efficacy and adverse events data from a phase II trial in Allan-Herndon-Dudley syndrome released by Egetis Therapeutics
  • 13 Feb 2025 Registered for Allan-Herndon-Dudley syndrome (In neonates, In infants, In children, In adolescents, In adults, In the elderly) in European Union, Liechtenstein, Norway, Iceland (PO) - First global approval

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top